导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.74% | 1827/4773 |
| 近一周 | -1.64% | 614/5462 |
| 近一月 | -1.59% | 981/5421 |
| 近一季 | -4.33% | 1605/5209 |
| 近半年 | -3.37% | 2190/4920 |
| 近一年 | 3.43% | 1936/4366 |
| 近两年 | 53.49% | 1379/2954 |
| 近三年 | 36.59% | 816/2253 |
| 成立以来 | 157.03% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.38% 2267/4961 |
8.33% 2606/5312 |
- - |
- - |
| 2025 | 18.77% 2283/4813 |
-1.95% 2821/3635 |
5.37% 604/4076 |
14.67% 2883/4524 |
0.24% 2104/4813 |
| 2024 | 22.16% 393/3463 |
4.54% 449/2808 |
-0.69% 819/3014 |
15.04% 1833/3129 |
2.29% 965/3463 |
| 2023 | -4.85% 697/2656 |
7.10% 604/2280 |
-1.47% 494/2385 |
-2.94% 798/2515 |
-7.10% 2052/2655 |
| 2022 | -15.59% 423/2207 |
-11.44% 509/1919 |
4.86% 967/2016 |
-11.27% 521/2113 |
2.44% 937/2208 |
| 2021 | 10.16% 442/1822 |
-1.28% 460/1255 |
7.18% 696/1330 |
3.51% 404/1466 |
0.57% 1091/1822 |
| 2020 | 36.22% 399/1250 |
-6.99% 519/1028 |
11.37% 735/1067 |
16.39% 154/1164 |
12.98% 404/1184 |
| 2019 | 29.64% 500/1092 |
27.77% 334/754 |
-2.85% 366/804 |
-1.66% 673/850 |
6.20% 641/918 |
| 2018 | -21.93% 226/834 |
- - |
- - |
- - |
-10.62% 209/691 |
| 2017 | 15.01% 249/714 |
- - |
- - |
- - |
- - |
| 2016 | -12.96% 313/605 |
- - |
- - |
- - |
- - |
| 2015 | 11.44% 159/575 |
- - |
- - |
- - |
- - |
| 2014 | 53.94% 60/237 |
- - |
- - |
- - |
- - |
| 2013 | 3.76% 59/186 |
- - |
- - |
- - |
- - |
| 2012 | 3.95% 87/140 |
- - |
- - |
- - |
- - |
| 2011 | -31.27% 95/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中盘ETF VS. 长安沪深300非周期A(740101) |